Exicure (FRA:2H0) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H0 Exicure Inc FRA:2H0
32 GF Score
Price €1.41
GF Value €0.43
! 2 Warning Signs
View Full Analysis

What is Exicure Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:2H0
32GF Score
Exicure Inc FRA:2H0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exicure (FRA:2H0) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of €1.41 is trading 227.9% above its estimated GF Value™ of €0.43.

Key valuation signals for FRA:2H0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.43 vs. price of €1.41 (227.9% above fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:2H0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges XCUR:USA2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
32GF Score

Get the complete analysis for FRA:2H0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.41
Price
€0.43
GF Value